Welcome to our dedicated page for integ news (Ticker: integ), a resource for investors and traders seeking the latest updates and insights on integ stock.
Integrum (publ) is a pioneering medical technology company based in Sweden, listed on NASDAQ First North Growth Market under the symbol INTEG. The company specializes in the development and commercialization of the OPRA™ Implant System, a groundbreaking solution for amputees. Recently, Integrum secured full funding from the US Department of Defense to conduct a clinical study on transtibial amputations at the Walter Reed National Military Medical Center. This study, once completed, will provide valuable data for future regulatory processes and expansion of the OPRA™ Implant System. Led by CEO Rickard Brånemark, Integrum is dedicated to revolutionizing amputee care and improving the lives of individuals worldwide.
Rhea-AI Summary
Integrum (INTEG) will host a webcast presentation of its third quarter 2023/24 results on February 29, 2024, at 14:00 CEST. CEO Rickard Brånemark, CFO Jörgen Svanström, and US President Jeffrey Zanni will present in English. The report will be available at integrum.se, and the webcast can be accessed at finwire.tv.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
-
Rhea-AI Summary
Integrum (INTEG) announces the sale of OPRA Implant Systems worth SEK 3.5 million to the Center of Excellence in Kyiv, Ukraine, following the successful establishment of the center in December 2023. The company has trained and certified two senior surgeons to perform surgeries on amputees using the innovative implant system. The purchase aims to ensure continuous access to the OPRA Implant System. The disclosure contains information pursuant to the EU Market Abuse Regulation. The CEO, Rickard Brånemark, highlighted the urgent need for amputee care in Ukraine, especially following the Russian invasion. The company's implant system, which attaches directly to the skeleton, provides the best care for many amputees. The PR also includes contact information for more details and the Certified Adviser for Integrum. The press release can be found at the link provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
-
Rhea-AI Summary
Integrum (Nasdaq First North Growth Market: INTEG B) establishes a Center of Excellence in Kyiv to spearhead orthopedic treatment using OPRA™ Implant System for individuals who have suffered limb loss, addressing the increased need for amputee care in Ukraine following the Russian invasion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
Rhea-AI Summary
Integrum (Nasdaq First North Growth Market: INTEG B) plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data. The company aims to broaden the regulatory approval in the US for the OPRA Implant System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
-
Rhea-AI Summary
INTEG B - Integrum (publ) Expects Higher Q2 Revenue, Operating Profit, and Cash Flow, Preliminary Figures Show 36.2% Revenue Increase and 611.1% Operating Profit Surge
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
-
Rhea-AI Summary
Integrum (NASDAQ First North Growth Market: INTEG B) announces full funding from the US Department of Defense for a clinical study of OPRA™ Implant System on up to 30 patients with transtibial amputations. The study will be conducted at the Walter Reed National Military Medical Center. The FDA-approved study will provide crucial data for future regulatory processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
Rhea-AI Summary
Integrum (NASDAQ First North Growth Market: INTEG B) expects Q2 revenue, operating profit, and cash flow to exceed market expectations. Revenue expected at 27.5 MSEK, a 36.2% increase from last year. Operating profit expected at 6.4 MSEK, with an increase attributed to activity and improved cost structure. Cash flow expected at 3.4 MSEK. Complete results to be presented in the quarterly report for August - October 2023 on December 4, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
-
Rhea-AI Summary
Integrum's OPRA™ Implant system receives FDA approval for a clinical study on below-knee amputations in the US. The study will be conducted by the Walter Reed National Military Medical Center and is crucial for future approval of the system. CEO Rickard Brånemark considers this a significant milestone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
-
Rhea-AI Summary
Integrum announces entry into Turkish market with OPRA™ Implant system in collaboration with Medikon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.82%
Tags
FAQ
What is Integrum known for?
Integrum (publ) is known for its pioneering work in developing and commercializing the innovative OPRA™ Implant System for amputees.
What recent achievement did Integrum announce?
Integrum recently secured full funding from the US Department of Defense to conduct a clinical study on transtibial amputations.
Who will be performing the clinical study on transtibial amputations?
The study will be performed by top surgeons at the Walter Reed National Military Medical Center in Bethesda, Maryland.
How will Integrum use the data from the clinical study?
Integrum will utilize the data obtained from the clinical study to support any future regulatory processes and enhance the OPRA™ Implant System.
What is the goal of Integrum's CEO, Rickard Brånemark?
CEO Rickard Brånemark is committed to broadening the use of the OPRA™ Implant System to improve the lives of as many amputees as possible.
Who is the Certified Adviser for Integrum?
Erik Penser Bank serves as the Certified Adviser for Integrum.
When will Integrum's quarterly report for August - October 2023 be published?
The quarterly report will be published on December 4, 2023.
What is the expected revenue for Q2 at Integrum?
The revenue for Q2 is expected to be at 27.5 MSEK, representing a 36.2% increase compared to the previous year.
What is the significance of Integrum's OPRA™ Implant System in Ukraine?
Integrum's innovative implant system provides a superior option for amputees in Ukraine, especially following the recent conflict.
Where can I access the webcast presentation of Integrum's third quarter 2023/24 results?
The webcast will be available at https://www.finwire.tv/webcast/integrum/q3-presentation-2023/.
integ